Navigation Links
Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data,Show

Study Published in Vaccine Shows Strong Immune Response, Protection Against H9N2 Influenza Strain

ROCKVILLE, Md., April 02, 2007 /PRNewswire-FirstCall/ -- Novavax Inc.'s virus- like particle (VLP) vaccine triggered a robust immune response and provided protection against the H9N2 strain of avian influenza, according to pre- clinical data published in the online edition of the journal Vaccine.

Novavax's vaccine was tested in three animal models, including the ferret, which is the most predictive model for influenza vaccine effectiveness in humans. Ferrets experience flu symptoms very similar to people who are infected with the virus. Protection, as measured by a reduction in viral load, was assessed in vaccinated ferrets challenged with live H9N2 avian influenza. Like the H5N1 strain, the H9N2 strain initially spread among domestic poultry in Asia. Since then, it has been isolated from humans and is identified as having pandemic potential.

"This is the first time Novavax has measured the efficacy of our VLP vaccine against a live virus challenge in the very important ferret model," said Dr. Rick Bright, vice president of global influenza programs at Novavax. The Company previously conducted live virus challenge studies with the H5N1 strain in mice. "These data are very encouraging because the ferret is a more predictive model for efficacy in humans."

Virus-like particles mimic the three-dimensional structure of a virus but do not contain genetic material, so they cannot replicate or cause infection. As VLPs maintain functional properties of both influenza surface proteins (hemagglutinin and neuraminidase), they likely trigger multiple arms of the immune system to generate a broadly protective immune response.

Novavax has conducted several pre-clinical studies evaluating a number of its VLP vaccines against different strains of avian influenza. "All of the data we've accumulated to dat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
2. Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
10. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
11. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
(Date:10/8/2008)...-ICR as Vaccine Adjuvant, SAN DIEGO, Oct. 8 /PRNe...poration (TSX: NVN) today presented positive data ...l-like Receptor 3 agonist, Poly IC-Poly,Arginine (...yon, France.,Study results demonstrated Poly-ICR t...like Receptor 3 (TLR3) pathway. Data showed that,P...
(Date:10/7/2008)...cLaren Health Care and its Great,Lakes Cancer Inst...dical,minds to share the latest work underway arou... treatments. The October 11th symposium, hosted by...mal Saha, M.D., an,award-winning surgical oncologi...tal cancer has gained worldwide recognition and ha...
(Date:10/7/2008)...l/ - Burcon NutraScience,Corporation (TSX-V: BU) a...TM) canola protein isolates are GRAS (Generally Re...ety of food and beverage,applications. The product...ent evaluation by a panel of qualified experts in ... sciences, food allergies and pediatric,nutrition....
(Date:10/7/2008)...e/ -- A study published in the,scientific journal ...,reported that InVitria,s ( http://www.InVitria.co...s an effective replacement to bovine serum albumin...ground state of embryonic stem cell,self-renewal,"...combinant,albumin in place of animal-derived serum...
Breaking Medicine Technology:Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Grocery Shoppers Are Following Stars to More Nutritious Choices 633 1Grocery Shoppers Are Following Stars to More Nutritious Choices 633 2Grocery Shoppers Are Following Stars to More Nutritious Choices 633 3Grocery Shoppers Are Following Stars to More Nutritious Choices 633 4WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development 207 1WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development 207 2WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development 207 3XTL Biopharmaceuticals Announces Presentation of Novel Pre Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference 402 1XTL Biopharmaceuticals Announces Presentation of Novel Pre Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference 402 2Terumo Heart to Announce Results of European Clinical Trial of DuraHeart 28TM 29 LVAS at European Association of Cardiothoracic Surgeons Meeting in Se 204 1Terumo Heart to Announce Results of European Clinical Trial of DuraHeart 28TM 29 LVAS at European Association of Cardiothoracic Surgeons Meeting in Se 204 2
... Immediately Following Transurethral Resection,is ...RVINE, Calif., April 19, 2007 /PRNewswire-FirstCal...ced results of a Phase,2b study of EOquin, in non-...eclinical data of SPI (IRL)-1620 and satraplatin,a...f Cancer,Research, held at the Los Angeles Convent...
...SINESS WIRE)--Apr 18, 2007 - Critical,Therapeutics...clinical research demonstrating a role in chronic ...Group Box-1 protein (HMGB1), a,pro-inflammatory me...blished in the May 2007 issue of Nature Immunology...of DNA complexes that,can stimulate immune cells t...
Other Medicine Technology:Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 2Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 3Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 6Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 7Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 8Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5
(Date:10/11/2008)... Barnett International, a divis...nnounced the release of The Form FDA 1572: A Refer... Monitors. Designed for clinical investigators, cl...irs professionals, and others involved in the clin...ence guide to address the Form FDA 1572-Statement ...
(Date:10/10/2008)... likely to develop some form of disease by 20 year..., Oct. 10 (HealthDay News) -- Liver transplant pat...eneral population, say researchers in Finland. ,...f Liver Transplantation , researchers investigate...nsplant recipients from Helsinki University Centra...
(Date:10/10/2008)...LWAUKEE, Wis., Oct. 10 /PRNewswire/ -- More than 6...ember presidential election. This is the,result of...ld on Thursday,Oct. 9, at all of the health care ...total of 658 people signed up to vote at the drive...ined by the Wisconsin,Government Accountability Bo...
(Date:10/10/2008)... Upon the completion of a highl...sion of CDM Media proudly announces their next bus...f information technology executives in healthcare.... will launch May 10-12, 2009 at the Four Seasons R... Honolulu, HI (PRWEB) October 11, 2008 -- Upon th...
Breaking Medicine News(10 mins):Health News:Barnett Releases Reference Guide on Form FDA 1572--Statement of Investigator 2Health News:Barnett Releases Reference Guide on Form FDA 1572--Statement of Investigator 3Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2
...ork-Presbyterian Hospital/Weill Cornell Medical Ce...nts the ability of an antibody to directly target ...ing healthy tissues unharmed. The Phase I clinica..., targeted to the prostate specific membrane antig...
...y 40% of the doctors in one Russian city have late...ho work in TB clinics. The research has been publi...oblem worldwide. Russia is one country where it is... third of the world's population are infected with...
... standard breast cancer therapy drug tamoxifen, to...s by almost one-fifths. Publishing their finding... Dr. Francesco Boccardo of the National Cancer Res... changing treatments tracks to exemestane after 2 ...
...r from persistent iron overload has been cleared. ...um. Patients suffering from a rare genetic condit...se need regular blood transfusions. Generally thes... at nights by needle and pump which lasts for arou...
Other Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: